Eli Lilly reported a 48% revenue surge to $22.97 billion, beating estimates of $20.93 billion, fueled by cardiometabolic volume plus early oncology and immunology contributions. Non-GAAP margins expanded sharply to 54.8%, up 9 points year-over-year, while EPS reached $8.38 versus the $6.07 consensus. International markets accelerated with China up 93% and rest-of-world 136% in constant currency, alongside pipeline progress on oral and triple-agonist assets like retatrutide and Foundayo.

Despite self-pay comprising 55% of new Zepbound scripts, management highlighted diversification and capacity expansion, including a new genetic medicine facility, positioning the company beyond supply-constrained growth.

Company: Eli Lilly and Company (LLY) — Q2 FY2026

🎙️ Want podcasts like this on any of 5,000+ companies? Podfolio turns earnin ...